COYA 201 / Coya Therap - LARVOL DELTA

Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results (Businesswire) - "Coya Therapeutics...COYA 301 for FTD: IND filing and initiate Phase 1 (H2 2023); interim Data (H2 2023)....COYA 302 for neurodegenerative diseases: file IND and initiate Phase 1 (H2 2023)....COYA 201 for neurodegenerative, autoimmune, and metabolic diseases: Completion of Therapeutic Animal Model Studies (1H 2023)....COYA 101 for ALS: Initiate Phase 2b with grant funding or collaborative partnership (2024)."

Licensing / partnership • New P1 trial • New P2b trial • Alzheimer's Disease • Amyotrophic Lateral Sclerosis

Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics (GlobeNewswire) - “Coya Therapeutics, Inc…announced that it has raised approximately $10.3 million from institutional and accredited investors. The financing brings the total funding to date to over $20 million. Proceeds will be used to advance several key therapeutic programs which include: COYA 101, a scalable and expanded autologous Treg cell therapy for amyotrophic lateral sclerosis (ALS) patients, into a well-powered Phase 2b study; COYA 201, an autologous Treg-derived exosome therapeutic for ALS patients into Phase 1 studies; COYA 202, an allogeneic Treg-derived exosome therapeutic for frontal temporal dementia (FTD) into Phase 1 studies…Coya is also preparing a novel biologic program for IND submission for ALS, FTD, and Alzheimer’s disease patients.”

Financing • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Frontotemporal Lobar Degeneration